Events

EIPM Special Seminar "Counting What Matters: Quantitative Spatial Proteomics for Complex Tissues" with James R. Mansfield VP Business Development Imaging, Standard BioTools Seminar: 1pm-2pm ET Q&A Session: 2pm-3pm ET Abstract: Biology is spatial, and spatial imaging methods are increasingly being asked to do more. Complex cell types like cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) are defined by combinations of dozens of markers and graded expression levels, not simple on/off calls. Therapies such as antibody-drug conjugates (ADCs) add further layers: target expression, payload delivery, downstream pathway activation, and immune context all need resolving in the same tissue. Imaging Mass Cytometry (IMC) is ideal for this. It measures 40+ proteins in a single pass with no spectral overlap, and its linear dynamic range supports precise quantitation of both low- and high-abundance targets. IMC is also a simple choice for same-slide multiomics, layering protein data onto Xenium, MALDI, and/or H&E sections to connect transcript, metabolite, and morphology to protein function. Assay development is simple too. Staining uses a cocktail of primary antibodies, so panel development comes down to one all-markers-at-once titration, typically about a day. With nearly 300 validated antibodies in 30+ panels, including ADC panels with markers of downstream payload effects, and the ability to label any clone, new targets and pathway markers can be added quickly, even for complex cell types like CAFs and TAMs. This talk covers how these tools work together. IMC is already available at Weill Cornell through the Human Immune Monitoring Core, so getting started is simple. Biography: James R. Mansfield is a scientist with over 30 years of experience in biomedical imaging, with the past two decades focused on multiplex pathology and in situ immune cell phenotyping. He currently serves as Vice President of Imaging at Standard BioTools, where he leads efforts to advance the Hyperion Imaging System for high-dimensional tissue analysis. Prior to this, he was Senior Vice President at Visiopharm, where he helped develop the Phenoplex multiplex analysis platform. Earlier in his career, he managed the Vectra multiplex imaging system and inForm software at PerkinElmer, helping to establish core technologies now widely used in spatial biology. James is an associate editor of the American Journal of Nuclear Medicine and Molecular Imaging, holds seven patents, and has authored over 60 scientific publications. He is a frequent invited speaker and has served as a session chair and organizer at numerous international meetings in molecular imaging, digital pathology, and spatial omics.

Englander Institute for Precision Medicine | AI Working Group “Virtual T cell modeling to uncover exhaustion-reversing genetic perturbations in T cells within preinvasive lung adenocarcinoma,” Presented by: Nishanth Chinnadurai, MS Graduate Student Computational Biology Weill Cornell Medical College

EIPM Precision Medicine Research Conference Thursday, October 15, 2026 11AM-12PM via Zoom ONLY “Germline Susceptibility in Biliary Tract Cancer: The Unresolved Significance of Uncertain Variant” Presented by: Andrea Perra, MD, PhD Full Professor of Pathology, Specialist in Internal Medicine, University of Cagliari National Coordinator, HEAL ITALIA Precision Medicine Laboratories Coordinator of the UniCa-HEAL ITALIA Biobank, HEAL ITALIA foundation, Italy * This activity has been approved for AMA PRA Category 1 Credit(s)™*

Bio-Digital Twins for Precision Oncology: Predicting and Redirecting Resistant Cancer States Bishoy Faltas, MD Associate Professor of Medicine Associate Professor of Cell & Developmental Biology Chief Research Officer at the Englander Institute for Precision Medicine Weill Cornell Medicine

Englander Institute for Precision Medicine Seminar Series "The Human Glycome Project – What did we learn from the first 300,000 Human Glycomes” Presented By: Gordan Lauc, Ph.D. Professor of Biochemistry and Molecular Biology, University of Zagreb, Director, National Centre of Scientific Excellence in Personalized Healthcare, Honorary Professor, King's College London Dr. Gordon Lauc'c Biography: Gordan Lauc is a Professor of Biochemistry and Molecular Biology at the University of Zagreb, Director of the National Centre of Scientific Excellence in Personalised Healthcare, Honorary Professor at King's College London, and a member of the Johns Hopkins Society of Scholars. In 2017, he initiated the launch of the Human Glycome Project and serves as one of its two co-directors. His research team is pioneering high-throughput glycomic analysis and the application of glycan biomarkers in the field of precision medicine. By combining glycomic data with extensive genetic, epigenetic, biochemical, and physiological data from over 300,000 individuals, he aims to understand the role of glycans in normal physiology, ageing, and disease. Professor Lauchas co-authored over 300 research articles, which have been cited more than 20,000 times on Google Scholar. In 2007, he founded Genos, a biotech company that is currently the global leader in high-throughput glycomics. Research at Genos led to the development of the GlycanAge biological age test, which is used in over 2,000 clinics worldwide and is widely considered the premier tool for the personalisation of lifestyle interventions.

Englander Institute for Precision Medicine Journal Club Thursday, September 24, 2026 3:00 – 4:00 PM EST Belfer Research Building, Room 1401 https://weillcornell.zoom.us/j/92600608747 Zoom Meeting ID: 926 0060 8747 “AI-Enabled Virtual Spatial Proteomics from Histopathology for Interpretable Biomarker Discovery in Lung Cancer” Nature Medicine, January 2026 Presented by: Eda Nur Kozan, MD Research Pathology Fellow, Department of Pathology and Laboratory Medicine Englander Institute for Precision Medicine

Precision Medicine Research Conference Thursday, September 24, 2026 1-2PM via Zoom ONLY “Intravesical Mesothelin-based CAR TCells Targeting MUC16 EffectivelyControl Bladder Cancer in Preclinical Models” Presented by: Parwiz Abrahimi, MD, PhD Assistant Professor, Department of Urology, Assistant Professor, Department of Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center *THIS IS A SPECIAL NON-CME LECTURE*

Englander Institute for Precision Medicine – AI Clinic Join us for our AI Clinic meeting on Wednesday, September 23rd at 2:00pm ET. (note: more information will be covered outside of weekly topics) Topic of Discussion for this week "Making AI Work with Your Own Knowledge- How RAG Helps Researchers and Clinicians Get Better Answers" Session Leader: Bhavneet Bhinder, MS Senior Research Associate in Systems and Computational Biomedicine Englander Institute for Precision Medicine AI Clinic Info: EIPM's bi-weekly sessions (Wednesdays at 2pm-3pm) aim to enhance how we use LLMs for complex tasks, including coding. They will serve as a collaborative space for hands-on troubleshooting, knowledge sharing, and continuous learning. Who is this for? This clinic is designed for our entire scientific and clinical community, with a special emphasis on trainees (students, postdocs, residents and fellows). It is the perfect forum for: Researchers and Scientists looking to apply LLMs to data analysis, coding challenges, or manuscript writing.Clinicians interested in exploring how AI tools can securely optimize research and workflows.Trainees seeking a supportive, hands-on environment to learn and get guidance on applying advanced LLMs to their specific projects.What participants can expect from these sessions: Collaborate with our most LLM-proficient team members (“Super-Users”) to troubleshoot and refine their work.Present real challenges they are encountering (e.g., coding issues, complex prompts, workflow optimization).Potentially share “micro-presentations” when someone discovers a new model, feature, or technique.Our goals are to: Build internal expertise and share best practices. Help participants overcome real technical challenges, and create a community of practice around practical AI use. We are currently seeking Super-Users who demonstrate expertise in coding and experience with AI tools such as Chat GPT 5.2, Gemini 3.0, & Claude 4.5 Opus. We are also seeking participants who are looking for troubleshooting guidance. All skill levels are welcome, from beginners to advanced users. Reach out to Victoria Cummings (vjc4001@med.cornell.edu) should you have any questions or inquiries.

Englander Institute for Precision Medicine Seminar Series “Precision High-throughput Drug Screening in 3D Glioma Cerebral Organoids” Presented By: Stefano Cirigliano, Ph.D. Director, Glioblastoma Cerebral Organoid Core Assistant Professor of Research in Neuroscience “Identifying Selective Therapeutic Combinations for Ovarian Cancer High Throughput Drug Screening and Multi-Omic Integration” Presented By: Benjamin D. Hopkins, Ph.D. Director, Ex Vivo Models, Englander Institute for Precision Medicine Assistant Professor, Research in Systems and Computational Biomedicine Weill Cornell Medicine Abstract for “Precision High-throughput Drug Screening in 3D Glioma Cerebral Organoids” with Stefano Cirigliano, Ph.D. Glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults, remains incurable despite extensive research and clinical efforts. The use of preclinical models that fail to accurately replicate the biological complexity of human disease for drug screening has been suggested as a contributing factor to our inability to identify clinically effective drugs for GBM. Our lab has developed the cerebral organoid glioma (GLICO) model, a co-culture of human cerebral organoids and patient-derived glioma stem cells (GSCs). The GLICO model better recapitulates the human GBM microenvironment and intratumor heterogeneity, making it a promising model for improved drug screening. The use of the GLICO model as a novel patient-specific drug screening assay will rely on developing tools to precisely assess tumor cell viability in real-time and at multiple time points within a normal cerebral organoid (CO) without disrupting the organoid. Traditional in vitro tumor organoid viability assays, however, fail to distinguish between cell populations and are endpoint-destructive, preventing analysis of tumor response over time. To address these limitations, we present a novel, non-destructive, and automatable luminescence-based tumor tracking system compatible with both cell-autonomous and co-culture 3D tumor models. Our system detected drug responses in both GSCs and GLICOs with high reproducibility across manual and high-throughput settings. Notably, GSCs exhibited differential responses to the same treatments in GSCs versus GLICOs, underscoring the significance of integrating more physiologically relevant 3D organoid models into drug screening. Our platform provides a novel, sensitive, and robust tumor tracking platform, enabling real-time, non-destructive measurement of GSC viability within the clinically relevant GLICO model, improving the predictive value of drug screening and precision medicine for GBM. Abstract for “Identifying Selective Therapeutic Combinations for Ovarian Cancer High Throughput Drug Screening and Multi-Omic Integration” with Benjamin D. Hopkins, Ph.D. Ovarian cancer remains a therapeutic challenge due to rapid development of treatment resistance andlimited alternative options when standard-of-care therapies fail. High-throughput drug screening provides a powerful approach to systematically identify novel agents with selective activity against tumor cells. Our work leverages functional drug-response profiling across a genetically diverse panel of patient-derived organoid models to identify tumor-selective agents while simultaneously assessing potential off-target toxicity. Using the Kinome Library, we comprehensively screen for functional kinase dependencies across these diverse models, revealing that ovarian cancers specific dependencies. To develop rational multi-agent combinations, we integrate ReFLEX multi-omic analysis to map drug-induced adaptive signaling and identify complementary therapeutic regimens. By combining functional screening with multi-omic insights, we construct evidence-based drug combinations targeting interconnected pathways, maximizing efficacy while aiming to minimize toxicity and resistance emergence. This integrated screening approach establishes a scalable platform for discovering selective therapeutics and rationally designing combination regimens.

Precision Medicine Research Conference Thursday, September 10, 2026 1-2PM Belfer Research Building, Room 1401 and via Zoom “Bio-Digital Avatars for Personalized Sequencing of Bladder Cancer Therapies” Presented by: Bishoy Faltas, MD Chief Research Officer & Director of Bladder Cancer Research, Englander Institute for Precision Medicine Gellert Family-John P. Leonard, MD Research Scholar, Associate Professor of Medicine, Cell and Developmental Biology, Weill Cornell Medicine * This activity has been approved for AMA PRA Category 1 Credit(s)™*